What's the single most important number from Syncom's FY26 results?

Standalone profit after tax grew 55.5% versus the prior year. That's the headline from the annual audited results for the year ended March 31, 2026.

Did the auditor flag any problems?

No. The report is unmodified, which is the standard clean opinion. The only note is a technical emphasis of matter on an earnings per share restatement, which is an accounting correction.

Does the filing reveal anything new about Syncom's strategy or business?

No. The rationale explicitly states the filing contains no unexpected or novel information. It is a standard, routine annual results disclosure with no operational detail.

Is the strong profit growth reflected in the score of 5?

No. The score is a procedural outcome. The rationale notes that the annual financial results category is automatically assigned a fixed score range, making the 5 a rule-based assignment, not a judgment on the news value.

Earnings · Pharmaceuticals · Small cap

Syncom's FY26 profit jumped 55%. The filing adds nothing else.

A routine annual filing delivers strong growth but no drivers, no guidance, and no new narrative.

— 1 earlier story on Syncom Formulations (India) Ltd. →

SYNCOMF By Tipsheet Editorial 22 May 2026 · 6:54 PM IST Verify on BSE · NSE

Mkt cap₹1,306 cr

P/E17.08×

ROE14.45%

Debt / eq.0.01

+55.5% Year-on-year growth in standalone profit after tax.

What's new

Syncom reported standalone and consolidated audited results for FY26.
Standalone PAT rose 55.5% year-on-year.
The auditor's report was unmodified, with a technical note on EPS restatement.

Why this matters

A 55% jump in profit is a strong headline for any pharma company. The filing itself adds nothing to it. There's no commentary on drivers, margins, or outlook.

What we're watching

Whether management explains what drove the 55% profit growth.
Any dividend announcement alongside the results.
If this growth rate is sustained in FY27.

The full read

Syncom Formulations closed FY26 with standalone PAT up 55.5%. The annual audited results are routine. No surprises. The auditor's report is clean, with a technical note on an EPS restatement. The filing itself is a standard periodic disclosure. It confirms the profit growth. It does not explain it. There is no commentary on drivers, margins, or outlook. The next step is management commentary. None is here.

Questions answered

What's the single most important number from Syncom's FY26 results?: Standalone profit after tax grew 55.5% versus the prior year. That's the headline from the annual audited results for the year ended March 31, 2026.
Did the auditor flag any problems?: No. The report is unmodified, which is the standard clean opinion. The only note is a technical emphasis of matter on an earnings per share restatement, which is an accounting correction.
Does the filing reveal anything new about Syncom's strategy or business?: No. The rationale explicitly states the filing contains no unexpected or novel information. It is a standard, routine annual results disclosure with no operational detail.
Is the strong profit growth reflected in the score of 5?: No. The score is a procedural outcome. The rationale notes that the annual financial results category is automatically assigned a fixed score range, making the 5 a rule-based assignment, not a judgment on the news value.

Mentioned: Syncom Formulations (India) Ltd. · FY26 standalone results · March 31, 2026

Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Syncom Formulations (India) Ltd.

Pharmaceuticals

₹1,347 cr

P/E 17.62×

Latest quarter · Mar 2026

Sales₹135 cr

Net profit₹25 cr

Op. margin+16.3%

EPS₹0.27

Strength & growth

Debt / equity0.01×

Current ratio4.41×

Sales CAGR+10.9%

EPS CAGR+31.9%

Story so far

All notes on SYNCOMF →

22 May 2026 · 6:54 PM IST Syncom's FY26 profit jumped 55%. The filing adds nothing else.
45d ago Syncom Formulations profit jumps 55% as revenue gains slow